Ten industry associations endorse Declaration for Pharmaceutical Innovation at 2017 International Pharmaceutical Innovation Forum (IPIF)


22 March 2017 –NANJING: Ten leading domestic and foreign trade associations signed and endorsed  the Declaration for Pharmaceutical  Innovation today at the inaugural International Pharmaceutical Innovation  Forum (IPIF). The Declaration outlines the common vision shared by all signatories of how a sustainable  ecosystem can help foster drug innovation in China and support the realization  of the goals set forth in “Healthy China 2030”. This marks a significant step  for the pharmaceutical industry. IPIF is being held on March 22nd and 23rd in Nanjing, and is co-hosted by the R&D Based  Pharmaceutical Association Committee (RDPAC), the Nanjing Municipal Government,  and the Industrial Culture Development Center (ICDC), under the Ministry of  Industry and Information Technology (MIIT).   


In addition to the signing of the Declaration,  another leading action of the Forum is the establishment of a Coalition for  Innovation that will continue the work on the topics discussed at IPIF. IPIF  serves as a platform to facilitate high-level discussions between the Chinese  government and key players in the bio-pharmaceutical industry, including  academia, industry associations, government trade bodies, and key opinion  leaders.   


“This Forum and signing of the Declaration marks an important milestone for the pharmaceutical industry in China,” Mike  Dethick, Managing Director of RDPAC, announced in his opening speech. “The consensus  reached in Nanjing demonstrates the full support of key stakeholders in  recognizing the need to create a sustainable innovation ecosystem. RDPAC values  the opportunity to work with Jiangning District, Nanjing City, and ICDC to  build partnerships and engage in experience sharing, and we hope to continue  building upon this relationship as the Coalition’s work progresses.   



In 2016, RDPAC, along with three other domestic associations, jointly  conducted research and produced the report, “Fostering a Sustainable Ecosystem  for Drug Innovation in China” (hereinafter “Ecosystem Report”). The  recommendations of the Ecosystem Report serves as the backbone to the Declaration and many of the topics  addressed at IPIF. The Ecosystem Report found that the number of articles published in  high-quality life sciences journals rose from 4,000 in 2012 to more than 6,500  in 2015, the number of innovative drugs in the clinical trial phase increased  from 21 in 2011 to 69 in 2015, the number of pipeline compounds hit 656 in 2015,  indicating that China’s drug innovation ecosystem has begun to take shape and  that the bio-pharmaceutical industry is well-poised to drive innovation. It is  necessary for China to further advance in taking steps to create a sustainable  drug innovation ecosystem. To move in this direction, the Ecosystem Report  cites the need for a top-down design at the central government level and for  all elements along the innovation chain, including basic R&D, clinical  research, the regulatory process, and procurement and reimbursement to be  supported by scientific guiding principles and sound policies and mechanisms.  At the same time, intellectual property rights protection and capital  investment must be advanced.  


In addition to focusing on the innovation ecosystem, the Forum also  explores discourse on other important issues in healthcare: panel sessions will  feature topics on robust research and development capabilities in the global  R&D context, improving patient access to innovative medicine, and enabling inward  and outbound investment to drive innovation.   



Eric Bouteiller, Chair of RDPAC, highlighted, “the most important  outcome of establishing and promoting a sustainable drug innovation ecosystem  will be its benefit to patient wellbeing. As the medical industry advances at a  rapid rate, all stakeholders – industry, government, academia – need to work  together in translating investments in R&D and medical achievements into  direct benefits for patients.”   


The Forum is attended by over 300 Chinese and foreign experts, industry  leaders, and policy makers. Senior-level officials from the MIIT, the National  Health and Family Planning Commission (NHFPC), the Ministry of Human Resources  and Social Security (MOHRSS), and the China Food and Drug Administration (CFDA)  are also in attendance.  


Associations endorsing the Declaration:  


Biotechnology Innovation Organization (BIO)  

China Chamber of Commerce for Import & Export of Medicines &  Health Products (CCCMHPIE)  

China Nonprescription Medicines Association (CNMA)  

China Pharmaceutical Association of Plant Engineering (CPAPE)  

China Pharmaceutical Industry Association (CPIA)  

Chinese Pharmaceutical Enterprises Association (CPEA)  

European Federation of Pharmaceutical Industries and Associations  (EFPIA)  

Japan Pharmaceutical Manufacturers Association (JPMA)  

Pharmaceutical Research and Manufacturers of America (PhRMA)  

R&D-based Pharmaceutical Association Committee (RDPAC)  

Related articles: